Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.

<h4>Background</h4> <p>Vedolizumab specifically recognizes the 47 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression. </p> <h4>Aims</h4> <p>To review the safety of vedolizumab and summarise p...

Full description

Bibliographic Details
Main Authors:	Bye, W, Jairath, V, Travis, S
Format:	Journal article
Language:	English
Published:	Wiley 2017

Similar Items

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
by: Travis, S, et al.
Published: (2018)

Respiratory tract infections in patients with inflammatory bowel disease: safety analyses from vedolizumab clinical trials
by: Feagan, BG, et al.
Published: (2018)

Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: A cochrane systematic review and meta-analysis
by: Bye, W, et al.
Published: (2018)

Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experience
by: Feagan, B, et al.
Published: (2017)

Strategies for detecting colon cancer in patients with inflammatory bowel disease
by: Bye, W, et al.
Published: (2017)

Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases
by: Lynch, K, et al.
Published: (2019)

International experience of vedolizumab in primary sclerosing cholangitis and inflammatory bowel disease
by: Williamson, K, et al.
Published: (2018)

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
by: Bhayat, F, et al.
Published: (2017)

Vedolizumab for the treatment of chronic pouchitis
by: Travis, S, et al.
Published: (2023)

Mucosal healing in inflammatory bowel diseases: a systematic review.
by: Neurath, M, et al.
Published: (2012)

What is the optimal treatment for anemia in inflammatory bowel disease?
by: Kent, A, et al.
Published: (2012)

Thrombosis in inflammatory bowel disease: are we tailoring prophylaxis to those most at risk?
by: Bryant, R, et al.
Published: (2014)

Thrombosis in inflammatory bowel disease: Are we tailoring prophylaxis to those most at riskα
by: Bryant, R, et al.
Published: (2014)

Salicylates for inflammatory bowel disease.
by: Travis, S, et al.
Published: (1994)

Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHAN
by: Ledder, O, et al.
Published: (2017)

Vedolizumab in pediatric inflammatory bowel disease: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
by: Ledder, O, et al.
Published: (2017)

Vedolizumab in paediatric Inflammatory Bowel Disease: A retrospective multi-centre experience From the paediatric IBD Porto Group of ESPGHAN
by: Ledder, O, et al.
Published: (2017)

Improving the quality of care for inflammatory bowel disease
by: Ye, B, et al.
Published: (2018)

Conventional medical management of inflammatory bowel disease.
by: Burger, D, et al.
Published: (2011)

Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
by: Andrews, J, et al.
Published: (2009)

Cyclosporin for the treatment of severe inflammatory bowel disease.
by: Baker, K, et al.
Published: (1989)

Prevention and treatment of osteoporosis in inflammatory bowel disease.
by: Lichtenstein, G, et al.
Published: (2006)

P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
by: Cohen, R, et al.
Published: (2019)

Conventional drug therapy for inflammatory bowel disease.
by: Bryant, R, et al.
Published: (2015)

Guidelines for the management of inflammatory bowel disease in adults.
by: Carter, M, et al.
Published: (2004)

The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
by: Cohen, R, et al.
Published: (2019)

Central Endoscopy Reading in Inflammatory Bowel Diseases
by: Panés, J, et al.
Published: (2016)

Letter: inflammatory bowel disease guidelines and conflicts of interest.
by: Eliakim, R, et al.
Published: (2013)

Probiotic vesicles as supplement for inflammatory bowel disease treatment
by: Pun, Song Yi
Published: (2023)

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
by: Fraser, A, et al.
Published: (2002)

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
by: Wellens, J, et al.
Published: (2021)

What's app? Electronic health technology in inflammatory bowel disease
by: Walsh, A, et al.
Published: (2018)

Patient-reported goals in inflammatory bowel disease: what’s the problem?
by: Wong, D, et al.
Published: (2021)

Atopy in inflammatory bowel disease.
by: Mee, A, et al.
Published: (1979)

Genetics of inflammatory bowel disease.
by: Satsangi, J, et al.
Published: (1998)

Immunology of inflammatory bowel disease.
by: Jewell, D, et al.
Published: (1985)

The genetics of inflammatory bowel disease.
by: Satsangi, J, et al.
Published: (1997)

Genetics of inflammatory bowel disease.
by: Satsangi, J, et al.
Published: (1994)

Immunology of inflammatory bowel disease.
by: Hodgson, H, et al.
Published: (1987)

Arthritis and inflammatory bowel disease.
by: Wordsworth, P
Published: (2000)